Tel: +49 6172 686-0
About Fresenius Kabi
Fresenius Kabi is a global health care company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients. Fresenius Kabi’s product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the medical devices for administering these products. Within transfusion technologies, Fresenius Kabi offers products for collection and processing of blood components and for therapeutic treatment of patient blood by apheresis systems.
43 articles with Fresenius Kabi
Omnicell and Fresenius Kabi Collaborate to Enhance Management of Controlled Substances in U.S. Hospitals
Omnicell, Inc. and pharmacies, and Fresenius Kabi are collaborating to provide U.S. hospitals and health systems with innovative new pharmacy technology designed to support safety and efficiency in dispensing of controlled substances in patient care areas.
Fresenius Kabi Introduces New Simplist® Fentanyl Citrate Injection, USP 50 mcg per 1 mL in Ready-to-Administer Prefilled Syringe
Fresenius Kabi announced today the U.S. introduction of Fentanyl Citrate Injection, USP 50 mcg per 1 mL in its proprietary Simplist ® ready-to-administer prefilled syringe.
Fresenius Kabi announced today it has received a 2021 Supplier Legacy Award from Premier Inc. ( www.premierinc.com ), a leading health care improvement company.
Fresenius Kabi announced today the immediate availability of Temsirolimus Injection in the United States. Fresenius Kabi’s Temsirolimus Injection is supplied as a kit including one vial of 25 mg/mL Temsirolimus solution and one vial of diluent.
Fresenius Kabi Signs Exclusive U.S. Distribution Agreement with Corvida Medical for the HALO® Closed System Drug-Transfer Device
Fresenius Kabi Signs Exclusive U.S. Distribution Agreement with Corvida Medical for the HALO ® Closed System Drug-Transfer Device Enhances Fresenius Kabi’s extensive offerings in oncology care
The cancer drugmaker pled guilty of violating the Federal Food, Drug and Cosmetic Act by failing to provide certain records to investigators in federal court.
Fresenius Kabi Issues Voluntary Nationwide Recall of Ketorolac Tromethamine Injection, USP Due to the Presence of Particulate Matter
Fresenius Kabi USA is voluntarily recalling a single lot of Ketorolac Tromethamine Injection, USP, 30 mg/mL, 1 mL fill in a 2 mL amber vial to the user level due to the presence of particulate matter. Particulate matter was found in reserve sample vials. No adverse event reports have been received for the recalled lot, which was produced and sold in 2019. This press release features multimedia. View the full release
ScaleReady’s mission is to make the business of cell and gene therapy practical and viable by providing the most simple, scalable and versatile manufacturing platform in the industry
Fresenius Kabi Announces Availability of Acetaminophen Injection for Intravenous use in Ready-to-Use freeflex® Bags
Fresenius Kabi Announces Availability of Acetaminophen Injection for Intravenous use in Ready-to-Use free flex ® Bags Acetaminophen is an option for multimodal pain management in the perioperative period.
Fresenius Kabi and Kit Check today announced the companies have entered into an agreement under which Fresenius Kabi +RFID™ medications will be read by the Kit Check inventory management solution. The collaboration signals both companies’ commitment to medication safety and quality patient care acr
Fresenius Kabi Launches Icatibant Injection to Treat Acute Attacks of Hereditary Angioedema in Adults
Company’s first specialty drug is therapeutically equivalent to Firazyr ® and is a cost-effective generic alternative to currently marketed products for the treatment of acute attacks of hereditary angioedema Fresenius Kabi launches KabiCare patient support program in U.S. to promote access to essential medications
Veltassa® is a well-tolerated1 and effective2 oral calcium potassium binder for the treatment of hyperkalemia supported by 12 month clinical data
Fresenius Kabi announced it is introducing smart labels for a range of essential medications used in hospitals.
CORRECTING and REPLACING Fresenius Kabi Issues Voluntary Nationwide Recall of Two Lots of Dexmedetomidine Hydrochloride Injection Due to Cross-Contamination of Lidocaine
The date under the "Expiration Date" column for the row associated with Batch Number 6122207 should read: 06/2021.
Premier Inc. ProvideGx™ Program Partners with Fresenius Kabi to Secure the Supply of Sedation Drug Essential for COVID-19 Care
Premier Inc., through its ProvideGx™ program, has partnered with Fresenius Kabi to supply Diprivan® injectable emulsion, USP to healthcare providers, helping to stabilize the long-term supply of a medication vital for COVID-19 patient care.
Fresenius Kabi Expands MicroVault® Packaging to include Simplist® Morphine Sulfate Injection, USP Ready-to-Administer Prefilled Syringes
Fresenius Kabi Expands MicroVault ® Packaging to include Simplist ® Morphine Sulfate Injection, USP Ready-to-Administer Prefilled Syringes
Sedative that Received FDA Emergency Use Authorization Now Available from Fresenius Kabi for use in Mechanically Ventilated COVID-19 patients
Sedative that Received FDA Emergency Use Authorization Now Available from Fresenius Kabi for use in Mechanically Ventilated COVID-19 patients FDA authorization allows importation of Propoven 2% (propofol 20 mg per mL), double the concentration of the widely used drug Diprivan ® COVID-19 patients requiring mechanical ventilation increased demand for propofol worldwide LAKE ZURICH, Ill.--( BUSINESS WIRE )-- Fresenius Kabi announced today t
Pegfilgrastim is used to fight infection in patients undergoing chemotherapy by stimulating the body’s production of white blood cells Fresenius Kabi’s first U.S. biosimilar candidate
First-to-market generic for Mycamine ® provides cost-effective option Creates additional anti-infective supply for customers LAKE ZURICH, Ill.--( BUSINESS WIRE )-- Fresenius Kabi announced today the immediate availability in the United States of Micafungin for Injection. Fresenius Kabi’s Micafungin for Injection is available in 50 mg and 100 mg strengths in a 10 mL vial. This press release features multimedia. View the full release here: https
CORRECTING and REPLACING CAPTIONS Fresenius Kabi Issues Voluntary Nationwide Recall of 13 Lots of Ketorolac Tromethamine Injection, USP Due to the Presence of Particulate Matter in Reserve Samples
Fresenius Kabi USA, LLC is voluntarily recalling Ketorolac Tromethamine Injection, USP, 60 mg/2 mL, 2 mL fill in a 2 mL amber vial to the user level due to the presence of particulate matter.